FDA Expands Indication for Sotatercept-csrk in Pulmonary Arterial Hypertension
The FDA has approved an updated indication for sotatercept-csrk (WINREVAIR), an activin signaling inhibitor, for adults with pulmonary arterial hypertension (PAH) in WHO functional class III or IV.
Results from the phase 3 ZENITH trial showed that sotatercept-csrk significantly reduced the risks of death, lung transplantation, and PAH-related hospitalizations compared with placebo.
WINREVAIR was initially approved based on the pivotal STELLAR study in March 2024. Today’s approval expanded the indication of WINREVAIR to include components of the clinical worsening events: hospitalization for PAH, lung transplantation and death.
Author's summary: FDA expands WINREVAIR indication for PAH.
More News
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- VisitMalta Wins Gold At US Travel Awards For Second Year In A Row
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Over 2,700 People Denied Maltese Citizenship In Past Five Years